Paper36746385
The Rescue on Reperfusion Damage in Cerebral Infarction by Nelonemdaz (RODIN) Trial: Protocol for a Double-Blinded Clinical Trial of Nelonemdaz in Patients with Hyperacute Ischemic Stroke and Endovascular Thrombectomy.
Lee JS and 10 others. J Stroke, 2023. Cited by 15 papers, by iCite.
Cite this record
ConductScience Library. The Rescue on Reperfusion Damage in Cerebral Infarction by Nelonemdaz (RODIN) Trial: Protocol for a Double-Blinded Clinical Trial of Nelonemdaz in Patients with Hyperacute Ischemic Stroke and Endovascular Thrombectomy. Papers, record 36746385. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36746385
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
The Rescue on Reperfusion Damage in Cerebral Infarction by Nelonemdaz (RODIN) Trial: Protocol for a Double-Blinded Clinical Trial of Nelonemdaz in Patients with Hyperacute Ischemic Stroke and Endovascular Thrombectomy.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| GNT pharma | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05041010 | Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz | Derived from the trial | Yes |
Source ClinicalTrials.gov
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21152450 | Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. | Drug News Perspect | 2010 | https://conductscience.org/library/papers/21152450 | PubMed |
| 2 | 33765729 | Factors Contributing to an Efficacious Endovascular Treatment for Acute Ischemic Stroke in Asian Population. | Neurointervention | 2021 | https://conductscience.org/library/papers/33765729 | PubMed |
| 3 | 22394615 | Neuroprotection for ischaemic stroke: translation from the bench to the bedside. | Int J Stroke | 2012 | https://conductscience.org/library/papers/22394615 | PubMed |
| 4 | 17106444 | Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine. | J Cereb Blood Flow Metab | 2007 | https://conductscience.org/library/papers/17106444 | PubMed |
| 5 | 25517348 | A randomized trial of intraarterial treatment for acute ischemic stroke. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25517348 | PubMed |
| 6 | 25671798 | Randomized assessment of rapid endovascular treatment of ischemic stroke. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25671798 | PubMed |
| 7 | 36065810 | Nelonemdaz for Patients With Acute Ischemic Stroke Undergoing Endovascular Reperfusion Therapy: A Randomized Phase II Trial. | Stroke | 2022 | https://conductscience.org/library/papers/36065810 | PubMed |
| 8 | 8577361 | Blockade of glutamate receptors unmasks neuronal apoptosis after oxygen-glucose deprivation in vitro. | Neuroscience | 1995 | https://conductscience.org/library/papers/8577361 | PubMed |
| 9 | 10657404 | Selfotel in acute ischemic stroke : possible neurotoxic effects of an NMDA antagonist. | Stroke | 2000 | https://conductscience.org/library/papers/10657404 | PubMed |
| 10 | 33192266 | Excitotoxicity: Still Hammering the Ischemic Brain in 2020. | Front Neurosci | 2020 | https://conductscience.org/library/papers/33192266 | PubMed |
| 11 | 21372310 | Barthel index for stroke trials: development, properties, and application. | Stroke | 2011 | https://conductscience.org/library/papers/21372310 | PubMed |
| 12 | 15842354 | Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. | J Thromb Haemost | 2005 | https://conductscience.org/library/papers/15842354 | PubMed |
| 13 | 17272767 | Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. | Stroke | 2007 | https://conductscience.org/library/papers/17272767 | PubMed |
| 14 | 11730442 | Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. | JAMA | 2001 | https://conductscience.org/library/papers/11730442 | PubMed |
| 15 | 10441299 | Pathobiology of ischaemic stroke: an integrated view. | Trends Neurosci | 1999 | https://conductscience.org/library/papers/10441299 | PubMed |
| 16 | 12849400 | Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? | Lancet Neurol | 2002 | https://conductscience.org/library/papers/12849400 | PubMed |
| 17 | 32087818 | Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. | Lancet | 2020 | https://conductscience.org/library/papers/32087818 | PubMed |
| 18 | 25882376 | Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25882376 | PubMed |
| 19 | 29535893 | Temporal Changes in Care Processes and Outcomes for Endovascular Treatment of Acute Ischemic Stroke: Retrospective Registry Data from Three Korean Centers. | Neurointervention | 2018 | https://conductscience.org/library/papers/29535893 | PubMed |
| 20 | 23268106 | Antioxidant properties of Neu2000 on mitochondrial free radicals and oxidative damage. | Toxicol In Vitro | 2013 | https://conductscience.org/library/papers/23268106 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42864556 | Long-Term Quantitative MRI and Quality-of-Life After Endovascular Therapy in Acute Ischemic Stroke - A MR CLEAN-NO IV Substudy. | Transl Stroke Res | 2026 | https://conductscience.org/library/papers/42864556 | PubMed |
| 41188625 | New advances in small molecule drugs targeting NMDA receptors. | Acta Pharmacol Sin | 2026 | https://conductscience.org/library/papers/41188625 | PubMed |
| 40842809 | Neuroprotective Agents With Reperfusion Therapies in Ischemic Stroke: Evidence From Recent Randomized Trials. | Cureus | 2025 | https://conductscience.org/library/papers/40842809 | PubMed |
| 40533350 | Can CTA-Based Machine Learning Identify Patients for Whom Successful Endovascular Stroke Therapy Is Insufficient? | AJNR Am J Neuroradiol | 2025 | https://conductscience.org/library/papers/40533350 | PubMed |
| 40494590 | Early Administration of Nelonemdaz May Improve the Stroke Outcomes in Patients With Acute Stroke. | J Stroke | 2025 | https://conductscience.org/library/papers/40494590 | PubMed |
| 40325933 | In search of real-world cerebroprotection: An institutional perspective and review of the literature. | Interv Neuroradiol | 2025 | https://conductscience.org/library/papers/40325933 | PubMed |
| 39874036 | Nelonemdaz and Patients With Acute Ischemic Stroke and Mechanical Reperfusion: The RODIN Randomized Clinical Trial. | JAMA Netw Open | 2025 | https://conductscience.org/library/papers/39874036 | PubMed |
| 39684478 | The Therapeutic Effects of SP-8356, a Verbenone Derivative, with Multimodal Cytoprotective Mechanisms in an Ischemic Stroke Rat Model. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39684478 | PubMed |
| 38733445 | Insight into the pathophysiological advances and molecular mechanisms underlying cerebral stroke: current status. | Mol Biol Rep | 2024 | https://conductscience.org/library/papers/38733445 | PubMed |
| 38662299 | Excitotoxic Storms of Ischemic Stroke: A Non-neuronal Perspective. | Mol Neurobiol | 2024 | https://conductscience.org/library/papers/38662299 | PubMed |
| 38255965 | Neuroprotection during Thrombectomy for Acute Ischemic Stroke: A Review of Future Therapies. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38255965 | PubMed |
| 37959180 | Evolving Clinical-Translational Investigations of Cerebroprotection in Ischemic Stroke. | J Clin Med | 2023 | https://conductscience.org/library/papers/37959180 | PubMed |
| 36901765 | Neuroprotective Strategies for Ischemic Stroke-Future Perspectives. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36901765 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| DLG4 | 1742 | PubTator's text mining | https://conductscience.org/library/genes/1742 | NCBI Gene |
| GRIN2A | 2903 | PubTator's text mining | https://conductscience.org/library/genes/2903 | NCBI Gene |
| GRIN2B | 2904 | PubTator's text mining | https://conductscience.org/library/genes/2904 | NCBI Gene |
| NOS1 | 4842 | PubTator's text mining | https://conductscience.org/library/genes/4842 | NCBI Gene |
| PLAT | 5327 | PubTator's text mining | https://conductscience.org/library/genes/5327 | NCBI Gene |
| TAT | 6898 | PubTator's text mining | https://conductscience.org/library/genes/6898 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36746385
GET https://conductscience.org/api/papers/v1/36746385/references?page=2